{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:15:32Z","timestamp":1780676132272,"version":"3.54.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>Bempedoic acid is a novel therapeutic agent that is designed to reduce levels of low-density lipoprotein cholesterol (LDL-C). The purpose of this review is to provide the background for development of bempedoic acid, findings from clinical trials and to discuss clinical implications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>Bempedoic acid inhibits ATP citrate lyase within the liver and reduces cholesterol synthesis, with the potential to avoid muscle symptoms experienced by patients treated with statins. Early clinical studies demonstrated that administration of bempedoic acid resulted in lowering of LDL-C by 20\u201330% as monotherapy and by 40\u201350% when combined with ezetimibe, in addition to lowering of high sensitivity C-reactive protein by 20\u201330%. The CLEAR Outcomes trial of high cardiovascular risk patients, with elevated LDL-C levels and either unable or unwilling to take statins demonstrated that bempedoic acid reduced the rate of major adverse cardiovascular events. A greater incidence of elevation of hepatic transaminase and creatinine, gout, and cholelithiasis were consistently observed in bempedoic acid\u2013treated patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Bempedoic acid presents an additional therapeutic option to achieve more effective lowering of LDL-C levels and reduction in cardiovascular risk.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11883-024-01188-5","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T06:02:25Z","timestamp":1706680945000},"page":"83-89","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["How Will Our Practice Change After the CLEAR Outcomes Trial?"],"prefix":"10.1007","volume":"26","author":[{"given":"Timothy","family":"Abrahams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"1188_CR1","doi-asserted-by":"crossref","unstructured":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383\u20131389.","DOI":"10.1016\/S0140-6736(94)90566-5"},{"issue":"20","key":"1188_CR2","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","volume":"333","author":"J Shepherd","year":"1995","unstructured":"Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301\u20137.","journal-title":"N Engl J Med"},{"issue":"14","key":"1188_CR3","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","volume":"335","author":"FM Sacks","year":"1996","unstructured":"Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001\u20139.","journal-title":"N Engl J Med"},{"key":"1188_CR4","doi-asserted-by":"crossref","unstructured":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339(19):1349\u20131357.","DOI":"10.1056\/NEJM199811053391902"},{"key":"1188_CR5","doi-asserted-by":"crossref","unstructured":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7\u201322.","DOI":"10.1016\/S0140-6736(02)09327-3"},{"issue":"9753","key":"1188_CR6","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381.","journal-title":"Lancet"},{"issue":"25","key":"1188_CR7","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med"},{"issue":"22","key":"1188_CR8","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"key":"1188_CR9","doi-asserted-by":"crossref","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713\u201322.","DOI":"10.1056\/NEJMoa1615664"},{"key":"1188_CR10","unstructured":"\u2022\u2022 Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353\u201364. Total results of the CLEAR Outcomes study."},{"issue":"1","key":"1188_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"25","key":"1188_CR12","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082\u2013143.","journal-title":"Circulation"},{"issue":"32","key":"1188_CR13","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease 1 Evidence from genetic, epidemiologic, and clinical studies A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart. 2017;38(32):2459\u201372.","journal-title":"Eur Heart"},{"issue":"22","key":"1188_CR14","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","volume":"365","author":"SJ Nicholls","year":"2011","unstructured":"Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078\u201387.","journal-title":"N Engl J Med"},{"issue":"13","key":"1188_CR15","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","volume":"295","author":"SE Nissen","year":"2006","unstructured":"Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556\u201365.","journal-title":"JAMA"},{"issue":"9","key":"1188_CR16","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","volume":"291","author":"SE Nissen","year":"2004","unstructured":"Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071\u201380.","journal-title":"JAMA"},{"issue":"7","key":"1188_CR17","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.jacc.2005.07.006","volume":"46","author":"P Libby","year":"2005","unstructured":"Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005;46(7):1225\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"1188_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11883-016-0611-4","volume":"18","author":"O Bilen","year":"2016","unstructured":"Bilen O, Ballantyne CM. Bempedoic acid (ETC-1002): an investigational inhibitor of ATP citrate lyase. Curr Atheroscler Rep. 2016;18(10):61.","journal-title":"Curr Atheroscler Rep"},{"issue":"11","key":"1188_CR19","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1056\/NEJMoa1806747","volume":"380","author":"BA Ference","year":"2019","unstructured":"Ference BA, Ray KK, Catapano AL, et al. Mendelian randomization study of ACLY and cardiovascular disease. N Engl J Med. 2019;380(11):1033\u201342.","journal-title":"N Engl J Med"},{"issue":"1","key":"1188_CR20","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1194\/jlr.M030528","volume":"54","author":"SL Pinkosky","year":"2013","unstructured":"Pinkosky SL, Filippov S, Srivastava RA, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013;54(1):134\u201351.","journal-title":"J Lipid Res"},{"issue":"7","key":"1188_CR21","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1194\/jlr.M400018-JLR200","volume":"45","author":"CT Cramer","year":"2004","unstructured":"Cramer CT, Goetz B, Hopson KL, et al. Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome. J Lipid Res. 2004;45(7):1289\u2013301.","journal-title":"J Lipid Res"},{"issue":"13","key":"1188_CR22","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.jacc.2013.05.050","volume":"62","author":"CM Ballantyne","year":"2013","unstructured":"Ballantyne CM, Davidson MH, Macdougall DE, et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013;62(13):1154\u201362.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1188_CR23","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1161\/ATVBAHA.113.302677","volume":"34","author":"MJ Gutierrez","year":"2014","unstructured":"Gutierrez MJ, Rosenberg NL, Macdougall DE, et al. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014;34(3):676\u201383.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"1188_CR24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","volume":"9","author":"PD Thompson","year":"2015","unstructured":"Thompson PD, Rubino J, Janik MJ, et al. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol. 2015;9(3):295\u2013304.","journal-title":"J Clin Lipidol"},{"issue":"12","key":"1188_CR25","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1016\/j.amjcard.2016.03.043","volume":"117","author":"CM Ballantyne","year":"2016","unstructured":"Ballantyne CM, McKenney JM, MacDougall DE, et al. Effect of ETC-1002 on serum low-density lipoprotein cholesterol in hypercholesterolemic patients receiving statin therapy. Am J Cardiol. 2016;117(12):1928\u201333.","journal-title":"Am J Cardiol"},{"key":"1188_CR26","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","volume":"277","author":"CM Ballantyne","year":"2018","unstructured":"Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018;277:195\u2013203.","journal-title":"Atherosclerosis"},{"issue":"11","key":"1188_CR27","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","volume":"380","author":"KK Ray","year":"2019","unstructured":"Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022\u201332.","journal-title":"N Engl J Med"},{"issue":"18","key":"1188_CR28","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.2019.16585","volume":"322","author":"AC Goldberg","year":"2019","unstructured":"Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. JAMA. 2019;322(18):1780\u20138.","journal-title":"JAMA"},{"issue":"7","key":"1188_CR29","doi-asserted-by":"publisher","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","volume":"8","author":"U Laufs","year":"2019","unstructured":"Laufs U, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8(7):e011662.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"1188_CR30","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/2047487319864671","volume":"27","author":"CM Ballantyne","year":"2020","unstructured":"Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020;27(6):593\u2013603.","journal-title":"Eur J Prev Cardiol"},{"key":"1188_CR31","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.atherosclerosis.2020.12.023","volume":"320","author":"J Rubino","year":"2021","unstructured":"Rubino J, MacDougall DE, Sterling LR, Hanselman JC, Nicholls SJ. Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: a randomized clinical trial. Atherosclerosis. 2021;320:122\u20138.","journal-title":"Atherosclerosis"},{"key":"1188_CR32","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ahj.2020.10.060","volume":"235","author":"S Nicholls","year":"2021","unstructured":"Nicholls S, Lincoff AM, Bays HE, et al. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. Am Heart J. 2021;235:104\u201312.","journal-title":"Am Heart J"},{"key":"1188_CR33","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Nissen SE, Menon V, Nicholls SJ, et al. Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients. JAMA. 2023;330(2):131\u201340. Impact of bempedoic acid in high risk primary prevention patients.","DOI":"10.1001\/jama.2023.9696"},{"key":"1188_CR34","doi-asserted-by":"publisher","unstructured":"Nicholls SJ, Nelson AJ, Lincoff AM, et al. Impact of bempedoic acid on total cardiovascular events. A prespecified analysis of the CLEAR Outcomes randomized clinical trial. JAMA Cardiol. 2024. https:\/\/doi.org\/10.1001\/jamacardio.2023.5155.","DOI":"10.1001\/jamacardio.2023.5155"},{"issue":"1","key":"1188_CR35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S2213-8587(23)00316-9","volume":"12","author":"KK Ray","year":"2024","unstructured":"Ray KK, Nicholls SJ, Li N, et al. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. Lancet Diab Endocrin. 2024;12(1):19\u201328.","journal-title":"Lancet Diab Endocrin."},{"issue":"11","key":"1188_CR36","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray KK, Molemans B, Schoonen WM, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279\u201389.","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"1188_CR37","first-page":"685","volume":"22","author":"I Lin","year":"2016","unstructured":"Lin I, Sung J, Sanchez RJ, et al. Patterns of statin use in a real-world population of patients at high cardiovascular risk. J Manag Care Spec Pharm. 2016;22(6):685\u201398.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"1188_CR38","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bcp.12339","volume":"78","author":"MA De Vera","year":"2014","unstructured":"De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br J Clin Pharmacol. 2014;78(4):684\u201398.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"1188_CR39","doi-asserted-by":"publisher","first-page":"e185554","DOI":"10.1001\/jamanetworkopen.2018.5554","volume":"1","author":"K Khunti","year":"2018","unstructured":"Khunti K, Danese MD, Kutikova L, et al. Association of a combined measure of adherence and treatment intensity with cardiovascular outcomes in patients with atherosclerosis or other cardiovascular risk factors treated with statins and\/or ezetimibe. JAMA Netw Open. 2018;1(8):e185554.","journal-title":"JAMA Netw Open"},{"issue":"34","key":"1188_CR40","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","volume":"43","author":"I Bytyci","year":"2022","unstructured":"Bytyci I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43(34):3213\u201323.","journal-title":"Eur Heart J"},{"issue":"22","key":"1188_CR41","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1056\/NEJMc2031173","volume":"383","author":"FA Wood","year":"2020","unstructured":"Wood FA, Howard JP, Finegold JA, et al. N-of-1 trial of a statin, placebo, or no treatment to assess side effects. N Engl J Med. 2020;383(22):2182\u20134.","journal-title":"N Engl J Med"},{"issue":"3","key":"1188_CR42","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ahj.2013.06.004","volume":"166","author":"WM Mampuya","year":"2013","unstructured":"Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166(3):597\u2013603.","journal-title":"Am Heart J"},{"issue":"15","key":"1188_CR43","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/jama.2016.3608","volume":"315","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315(15):1580\u201390.","journal-title":"JAMA"},{"key":"1188_CR44","doi-asserted-by":"publisher","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","volume":"29","author":"KK Ray","year":"2023","unstructured":"Ray KK, Haq I, Bilitou A, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Eur. 2023;29:100624.","journal-title":"Lancet Reg Health Eur"},{"issue":"21","key":"1188_CR45","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195\u2013207.","journal-title":"N Engl J Med"},{"issue":"21","key":"1188_CR46","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","volume":"374","author":"S Yusuf","year":"2016","unstructured":"Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374(21):2021\u201331.","journal-title":"N Engl J Med"},{"issue":"16","key":"1188_CR47","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","volume":"81","author":"CM Ballantyne","year":"2023","unstructured":"Ballantyne CM, Banka P, Mendez G, et al. Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616. J Am Coll Cardiol. 2023;81(16):1553\u201364.","journal-title":"J Am Coll Cardiol"},{"key":"1188_CR48","doi-asserted-by":"crossref","unstructured":"Raal F, Fourie N, Scott R, et al. Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial. Eur Heart J 2023.","DOI":"10.1093\/eurheartj\/ehad596"},{"issue":"8","key":"1188_CR49","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","volume":"28","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls SJ, Ditmarsch M, Kastelein JJ, et al. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med. 2022;28(8):1672\u20138.","journal-title":"Nat Med"},{"issue":"7859","key":"1188_CR50","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","volume":"593","author":"K Musunuru","year":"2021","unstructured":"Musunuru K, Chadwick AC, Mizoguchi T, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. 2021;593(7859):429\u201334.","journal-title":"Nature"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-024-01188-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-024-01188-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-024-01188-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T09:09:06Z","timestamp":1708506546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-024-01188-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1188"],"URL":"https:\/\/doi.org\/10.1007\/s11883-024-01188-5","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,31]]},"assertion":[{"value":"10 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.J.N. has received research support from AstraZeneca, Amgen, Anthera, CSL Behring, Cerenis, Eli Lilly, Resverlogix, New Amsterdam Pharma, Novartis, InfraReDx and Sanofi-Regeneron. S.J.N. is also a consultant for Amgen, Akcea, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Esperion, Kowa, Merck, Takeda, Pfizer, Sanofi- Regeneron, Vaxxinity, CSL Sequiris, and Novo Nordisk. S.J.N. also reports grants and personal fees from Esperion. A.J.N. has received research support and consulting fees from Amgen and Novartis. T.A. has no relationships to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}